KESKİNKILIÇ, M. Et Al. 2024. The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials. Breast , vol.78 .

KESKİNKILIÇ, M., ARAYICI, M. E., BAŞBINAR, Y., ELLİDOKUZ, H., YAVUZŞEN, T., & ÖZTOP, İ., (2024). The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials. Breast , vol.78.

KESKİNKILIÇ, MERVE Et Al. "The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials," Breast , vol.78, 2024

KESKİNKILIÇ, MERVE Et Al. "The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials." Breast , vol.78, 2024

KESKİNKILIÇ, M. Et Al. (2024) . "The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials." Breast , vol.78.

@article{article, author={MERVE KESKİNKILIÇ Et Al. }, title={The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials}, journal={Breast}, year=2024}